Neogenomics (NEO) Cash & Equivalents (2010 - 2026)

Neogenomics (NEO) has reported Cash & Equivalents for 17 consecutive years, with $146.1 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $146.1 million, down 57.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.1 million (down 57.79% YoY), and the FY2025 annual result was $159.6 million, down 56.51% from the prior year.
• Cash & Equivalents was $146.1 million for Q1 2026 at Neogenomics, down from $159.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $367.0 million in Q4 2024 and troughed at $146.1 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $277.6 million, with a median of $289.1 million recorded in 2023.
• Year-over-year, Cash & Equivalents jumped 30.13% in 2023 and slumped 57.79% in 2026.
• Over 5 years, Cash & Equivalents stood at $263.2 million in 2022, then soared by 30.13% to $342.5 million in 2023, then advanced by 7.16% to $367.0 million in 2024, then slumped by 56.51% to $159.6 million in 2025, then declined by 8.44% to $146.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $146.1 million in Q1 2026, $159.6 million in Q4 2025, and $164.1 million in Q3 2025.